Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

83 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
GLP-1R agonist therapy for diabetes: benefits and potential risks.
Samson SL, Garber A. Samson SL, et al. Curr Opin Endocrinol Diabetes Obes. 2013 Apr;20(2):87-97. doi: 10.1097/MED.0b013e32835edb32. Curr Opin Endocrinol Diabetes Obes. 2013. PMID: 23403741 Review.
Gene therapy for diabetes: reinventing the islet.
Samson SL, Chan L. Samson SL, et al. Trends Endocrinol Metab. 2006 Apr;17(3):92-100. doi: 10.1016/j.tem.2006.02.002. Epub 2006 Feb 28. Trends Endocrinol Metab. 2006. PMID: 16504534 Review.
Gene therapy for diabetes: metabolic effects of helper-dependent adenoviral exendin 4 expression in a diet-induced obesity mouse model.
Samson SL, Gonzalez EV, Yechoor V, Bajaj M, Oka K, Chan L. Samson SL, et al. Mol Ther. 2008 Nov;16(11):1805-12. doi: 10.1038/mt.2008.198. Epub 2008 Sep 9. Mol Ther. 2008. PMID: 18781141 Free PMC article.
Gene therapy with neurogenin 3 and betacellulin reverses major metabolic problems in insulin-deficient diabetic mice.
Yechoor V, Liu V, Paul A, Lee J, Buras E, Ozer K, Samson S, Chan L. Yechoor V, et al. Among authors: samson s. Endocrinology. 2009 Nov;150(11):4863-73. doi: 10.1210/en.2009-0527. Epub 2009 Oct 9. Endocrinology. 2009. PMID: 19819964 Free PMC article.
Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.
Sathyanarayana P, Jogi M, Muthupillai R, Krishnamurthy R, Samson SL, Bajaj M. Sathyanarayana P, et al. Among authors: samson sl. Obesity (Silver Spring). 2011 Dec;19(12):2310-5. doi: 10.1038/oby.2011.152. Epub 2011 Jun 9. Obesity (Silver Spring). 2011. PMID: 21660077 Clinical Trial.
Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.
Samson SL, Sathyanarayana P, Jogi M, Gonzalez EV, Gutierrez A, Krishnamurthy R, Muthupillai R, Chan L, Bajaj M. Samson SL, et al. Diabetologia. 2011 Dec;54(12):3093-100. doi: 10.1007/s00125-011-2317-z. Epub 2011 Sep 29. Diabetologia. 2011. PMID: 21956711 Free PMC article. Clinical Trial.
Potential of incretin-based therapies for non-alcoholic fatty liver disease.
Samson SL, Bajaj M. Samson SL, et al. J Diabetes Complications. 2013 Jul-Aug;27(4):401-6. doi: 10.1016/j.jdiacomp.2012.12.005. Epub 2013 Jan 24. J Diabetes Complications. 2013. PMID: 23352496 Review.
Ghrelin: much more than a hunger hormone.
Pradhan G, Samson SL, Sun Y. Pradhan G, et al. Among authors: samson sl. Curr Opin Clin Nutr Metab Care. 2013 Nov;16(6):619-24. doi: 10.1097/MCO.0b013e328365b9be. Curr Opin Clin Nutr Metab Care. 2013. PMID: 24100676 Free PMC article. Review.
Metabolic syndrome.
Samson SL, Garber AJ. Samson SL, et al. Endocrinol Metab Clin North Am. 2014 Mar;43(1):1-23. doi: 10.1016/j.ecl.2013.09.009. Endocrinol Metab Clin North Am. 2014. PMID: 24582089 Review.
Cardiovascular effects of incretin therapy in diabetes care.
Kim J, Samson SL. Kim J, et al. Among authors: samson sl. Metab Syndr Relat Disord. 2014 Aug;12(6):303-10. doi: 10.1089/met.2014.0035. Epub 2014 May 19. Metab Syndr Relat Disord. 2014. PMID: 24842063 Free PMC article. Review.
83 results
Jump to page
Feedback